- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04641754
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
November 17, 2020 updated by: Qilu Pharmaceutical Co., Ltd.
Phase II Clinical Study to Evaluate the Efficacy and Safety of WX-0593 in Patients With Crizotinib-resistant ALK -Positive, or Crizotinib-resistant/Crizotinib-naive ROS1-positive Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
Study Overview
Detailed Description
The clinical study is a single-arm, phase II, open label, multicenter design in patients with crizotinib-resistant ALK -positive, or crizotinib-resistant/crizotinib-naive ROS1-positive NSCLC.
Study Type
Interventional
Enrollment (Anticipated)
176
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230022
- Recruiting
- The First affiliated Hospital of Anhui Medical University
-
Hefei, Anhui, China, 233004
- Recruiting
- Oncology Department, Anhui Cancer Hospital
-
Hefei, Anhui, China, 233004
- Recruiting
- Respiratory Department, Anhui Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Beijing, Beijing, China, 100039
- Recruiting
- Chinese PLA General hospital
-
Beijing, Beijing, China, 101149
- Recruiting
- Beijing Chest Hospital
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
Beijing, Beijing, China, 100142
- Recruiting
- Thoracic Oncology I Department, Beijing Cancer Hospital
-
Beijing, Beijing, China, 100142
- Recruiting
- Thoracic Oncology II Department, Beijing Cancer Hospital
-
Beijing, Beijing, China, 101149
- Recruiting
- General Department, Beijing Chest Hospital, Capital Medical University
-
-
Chongqing
-
Chongqing, Chongqing, China, 400042
- Recruiting
- Army Medical Center of PLA
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Recruiting
- Fujian Cancer Hospital
-
-
Gansu
-
Lanzhou, Gansu, China, 620100
- Recruiting
- Gansu Cancer Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510095
- Recruiting
- Cancer Center of Guangzhou Medical University
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545006
- Recruiting
- Liuzhou people's Hospital
-
-
Hebei
-
Shijiangzhuang, Hebei, China, 050019
- Recruiting
- The Fourth Hospital of Hebei Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Recruiting
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430070
- Recruiting
- Hubei Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410006
- Recruiting
- Hunan Tumor Hospital
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China, 010000
- Recruiting
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Nanjing Chest Hospital
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Wuxi, Jiangsu, China, 214062
- Recruiting
- The Affiliated Hospital of Jiangnan University
-
Xuzhou, Jiangsu, China, 221009
- Recruiting
- Xuzhou Central Hospital
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Changchun, Jilin, China, 132000
- Recruiting
- Jilin cancer hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- Recruiting
- The First Hospital of China Medical University
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital of Shandong University
-
Jinan, Shandong, China, 250117
- Recruiting
- Shandong Cancer Hospital
-
Jinan, Shandong, China, 250013
- Recruiting
- Jinan Central Hospital
-
Qingdao, Shandong, China, 266555
- Recruiting
- The Affiliated Hospital of Qingdao University
-
Yantai, Shandong, China, 264000
- Recruiting
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030013
- Recruiting
- Shanxi Cancer Hospital
-
Xi'an, Shanxi, China, 710038
- Recruiting
- Tangdu Hospital
-
-
Sichuan
-
Nanchong, Sichuan, China, 637000
- Recruiting
- Affiliated Hospital of North Sichuan Medical College
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Recruiting
- Tianjin cancer hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830011
- Recruiting
- Cancer Hospital affiliated to Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China, 650100
- Recruiting
- Yunnan Cancer Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310006
- Recruiting
- Hangzhou First People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥18 years.
- Female or male;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Expected survival no less than 12 weeks.
- Patient should have at least one measurable lesion (RECIST 1.1); Lesions previously treated with radiotherapy can be considered target lesions only if there is a clear evidence of progression after radiotherapy.
Histologically or cytologically confirmed advanced ALK-positive NSCLC in upper first-class hospitals,or histologically or cytologically confirmed advanced ROS1-positive NSCLC in a central laboratory. Admission of ROS1-positive patients will be based on the positive test results confirmed by the central laboratory or by the local-approved method.
- Patients with ALK-positive NSCLC who had been progressive disease after at least 12 weeks of continuous treatment with crizotinib .
- Patients with ROS1-positive NSCLC who failed in standard treatment (eg.resistant /intolerance of crizotinib or chemotherapy).
- Patients with ROS1-positive NSCLC who cannot accept chemotherapy.
- ROS1-positive NSCLC patients who could not afford crizotinib treatment.
- Patients with or without asymptomatic CNS metastases, or symptomatic brain metastasis after treatment stabilized for more than 4 weeks, and with stopping systemic sex hormone therapy for more than 2 weeks.
- Organ functions should meet the following requirements (Blood components, cell growth factors, drugs that stimulate the growth of WBC or platelets, or drugs used to correct anemia are not permitted within 14 days prior to the laboratory examination): ANC≥1.5*10^9/L PLT≥90*10^9/L,Hb≥90 g/L, Total Bilirubin (TBIL)≤1.5*Upper Limit of Normal(ULN) ( Gilbert's Syndrome TBIL ≤3.0*ULN and DBIL≤1.5*ULN ),Alanine Transaminase (ALT)and Aspartate Aminotransferase (AST)≤2.5*ULN. For liver metastasis patients, ALT and AST≤5*ULN, Cr≤1.5*ULN, LVEF≥50%.
- Any surgery, prior radiotherapy (except for palliative radiotherapy)/procedures must be completed at least 4 weeks prior to starting the treatment with study drug. Palliative radiotherapy must be completed within 48 hours prior to starting treatment.
- Subject understands and voluntarily provides informed consent.
Exclusion Criteria:
- Received any prior ALK inhibitors other than crizotinib.
- Patients with brain meningeal metastasis.
- Any clinically significant cardiovascular disease within 6 months prior to the first dose of the investigational drug, including but not limited to: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident (including transient ischemic attack).
- Two consecutive corrected QT interval (QTc) > 480 ms through ECG examination during screening, patients with NCI-CTCAE v4.03 Grade ≥2 arrhythmia, Grade ≥2 heart failure, atrial fibrillation and ventricular fibrillation of any grade, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
- Concomitant use of medications that may cause QTc prolongation or induce Torsades de pointes within 14 days prior to the first dose of the investigational drug or during treatment.
- Continuous use of corticosteroids for more than 30 days, or require chronic use of corticosteroids or other immunosuppressants.
- Past history of a large area of diffuse/interstitial pulmonary fibrosis, or known history of Grade 3 or 4 interstitial pulmonary fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonitis, interstitial lung disease, obliterative bronchiolitis, or pulmonary fibrosis, but does not include local radiation pneumonitis or radiation-induced pulmonary fibrosis.
- Patients with Grade > 1 nausea, vomiting, or diarrhea (CTCAE 4.03), other GI dysfunction or GI disease that may potentially affect drug absorption (such as ulcerative disease or malabsorption syndrome).
- Subject received other clinical trial treatment within 1 month prior to the first dose of the investigational drug (if the medication received is a marketed drug, then refer to exclusion criteria #11).
- Patients who are HBsAg-positive and/or HBcAb positive and HBV DNA >10^3 copies/mL, or HCV antibody-positive, or syphilis antibody- positive or known HIV infected.
- No more than 2 weeks between the most recent use of another anti-cancer treatment (half life ≤3 days) and the first dose of the investigational drug, or the most recent use of another anti-cancer treatment (half life > 3 days) is less than 4 weeks. Patients previously treated with crizotinib could take WX-0593 tables after 1 week from the last dose.
- Patients who cannot suspend the use of a strong CYP3A4 inducer or inhibitor at least 1 weeks prior to this study and during the study. These drugs include but are not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, rifapentine, tipranavir, ritonavir, St. John's wart, and ketoconazole.
- Patients who cannot suspend the use of a CYP3A4 substrate at least 1 weeks prior to this study and during the study, and the therapeutic index is low.
- Pregnant or lactating female patients or a positive pregnancy test at baseline for females of childbearing potential.
- Childbearing potential female patients who are unwilling to use effective contraceptive measures during the entire course of the study and within 6 months after the end of the study, or male patients who plan to have children.
- Concurrent diseases that may seriously affect patient safety or impact patient completion of the study as determined by the investigator (such as clinically uncontrolled hypertension (blood pressure > 160/110 mmHg), severe diabetes, or thyroid disease).
- Drug or alcohol abuse. Alcohol abuse refers to drinking 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine.
- History of definitive neurological or mental disorder, including epilepsy or dementia.
- Patients with other malignant tumors within 3 years prior to screening (except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, thyroid carcinoma in situ, and papillary thyroid carcinoma).
- Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator and/or sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WX-0593 Tablets
60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
|
tablets, 60 mg→180mg, quaque die(QD)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Objective Response Rate (ORR) Assessed By An Independent Review Committee
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
ORR is defined the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR) per an Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after the initiation of study treatment.
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Objective Response Rate (ORR) Assessed By Investigators
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
ORR is defined the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR) per Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after the initiation of study treatment.
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Progression-free survival (PFS)
Time Frame: From frist administration of WX-0593 until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 18 weeks.
|
PFS defined as the time from baseline to first observed disease progression or death from any cause.
|
From frist administration of WX-0593 until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 18 weeks.
|
Disease Control Rate (DCR)
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
DCR is the percentage of patients with best response of CR, PR or Stable Disease (SD).
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Duration of Response (DOR)
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks .
|
The DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date on which progressive disease (PD) is first noted or date of death.
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks .
|
Time to Progression (TTP)
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Time to Progression
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Confirmed Intracranial Objective Response Rate (iORR)
Time Frame: From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Confirmed iORR is defined as the proportion of the participants who have achieved CR or PR in the brain per a modification of RECIST version 1.1, after the initiation of study treatment, in participants with intracranial brain metastases at baseline.
|
From frist administration of WX-0593 to the date that the last patients observed for 18 weeks.
|
Overall Survival (OS)
Time Frame: From frist administration of WX-0593 until death due to any cause, withdraws informed consent, is lost to follow-up or refuses phone visits, or study completion(up to 2.5 years)
|
OS is the time from the start of study treatment to the date of death.
|
From frist administration of WX-0593 until death due to any cause, withdraws informed consent, is lost to follow-up or refuses phone visits, or study completion(up to 2.5 years)
|
Incidence of Adverse Events
Time Frame: the date of written informed consent signed until at least 28 days after the last dose of study drug was administered.
|
Incidence of All Adverse Events, Serious Adverse Events and Treatment-Emergent Adverse Events by CTCAE v4.03
|
the date of written informed consent signed until at least 28 days after the last dose of study drug was administered.
|
Cssmin
Time Frame: Pre-dose on Cycle 1 Day 1, Cycle 1 Day 7, Cycle 1 Day 21, Cycle 2 Day 21, and Cycle 4 Day 21 (each cycle is 21 days)
|
Minimum value of steady plasma-drug concentration for WX-0593
|
Pre-dose on Cycle 1 Day 1, Cycle 1 Day 7, Cycle 1 Day 21, Cycle 2 Day 21, and Cycle 4 Day 21 (each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2019
Primary Completion (Anticipated)
December 1, 2020
Study Completion (Anticipated)
March 1, 2021
Study Registration Dates
First Submitted
November 11, 2020
First Submitted That Met QC Criteria
November 17, 2020
First Posted (Actual)
November 24, 2020
Study Record Updates
Last Update Posted (Actual)
November 24, 2020
Last Update Submitted That Met QC Criteria
November 17, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WX0593-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on WX-0593 Tablets
-
Pingping SongNot yet recruitingNon-Small Cell Lung Cancer(NSCLC)China
-
Qilu Pharmaceutical Co., Ltd.UnknownAdvanced Solid Tumor, Non-small Cell Lung CancerChina
-
Jinming YuRecruitingNon-small Cell Lung Cancer (NSCLC)China
-
Qilu Pharmaceutical Co., Ltd.Active, not recruitingNon-small Cell Lung CancerChina
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small Cell Lung CancerChina
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
Heidelberg Pharma AGU.S. Army Medical Research and Development CommandCompletedMetastatic Breast CancerUnited States, Belgium, Brazil, Germany, Israel
-
Heidelberg Pharma AGCompletedKidney CancerUnited States, Canada, Argentina, Brazil